Pfizer (PFE) Enterprise Value (2009 - 2026)
Pfizer (PFE) reported Enterprise Value of -$12.8 billion for Q1 2026, up 24.95% year-over-year from -$10.2 billion in Q1 2025, and up 3.95% quarter-over-quarter from -$13.3 billion in Q4 2025.
Pfizer (PFE) Enterprise Value (2009 - 2026) Analysis & Trends
Pfizer (PFE) has 18 years of Enterprise Value data on file, last reported at -$12.8 billion in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$12.8 billion, up 24.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.8 billion (up 24.95% YoY), and the FY2025 annual result was -$13.3 billion, up 34.12% from the prior year.
- Enterprise Value advanced to -$12.8 billion in Q1 2026 per PFE's latest filing, from -$13.3 billion in the prior quarter.
- Over five years, Enterprise Value peaked at -$6.8 billion in Q2 2024 and troughed at -$44.5 billion in Q3 2023.
- A 5-year average of -$20.9 billion and a median of -$17.0 billion in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 84.67% in 2024, then slumped 89.48% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$22.5 billion in 2022, then jumped by 44.76% to -$12.4 billion in 2023, then slumped by 62.56% to -$20.2 billion in 2024, then soared by 34.12% to -$13.3 billion in 2025, then grew by 3.95% to -$12.8 billion in 2026.
- Business Quant data shows PFE's Enterprise Value at -$12.8 billion in Q1 2026, -$13.3 billion in Q4 2025, and -$14.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -100.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -12.77 Bn |
| Dec 31, 2025 | -13.30 Bn |
| Sep 28, 2025 | -14.69 Bn |
| Jun 29, 2025 | -12.93 Bn |
| Mar 30, 2025 | -17.02 Bn |
| Dec 31, 2024 | -20.18 Bn |
| Sep 29, 2024 | -9.68 Bn |
| Jun 30, 2024 | -6.83 Bn |
| Mar 31, 2024 | -11.65 Bn |
| Dec 31, 2023 | -12.42 Bn |
| Oct 1, 2023 | -43.91 Bn |
| Jul 2, 2023 | -44.51 Bn |
| Apr 2, 2023 | -19.71 Bn |
| Dec 31, 2022 | -22.48 Bn |
| Oct 2, 2022 | -35.90 Bn |
| Jul 3, 2022 | -33.04 Bn |
| Apr 3, 2022 | -23.64 Bn |
| Dec 31, 2021 | -30.81 Bn |
| Oct 3, 2021 | -29.42 Bn |
| Jul 4, 2021 | -21.43 Bn |